PerkinElmer signs agreements with Johns Hopkins Univeristy and University of Birmingham (UK) to support cancer research

PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, announced today two multi-year research collaboration agreements with Johns Hopkins University and the University of Birmingham, United Kingdom, to establish the groundwork for developing cutting-edge tools and technologies for the discovery of biomarkers leading to diagnostics and personalized medicine.

The PerkinElmer BioEXPRESSION™ Platform is the premier solution for high throughput biomarker discovery and identification. Its carrier protein based biomarker enrichment technology is a new method in finding low abundance disease related biomarkers. PerkinElmer’s collaboration with Dr. Daniel W. Chan at the Johns Hopkins University and Dr. Philip Johnson at the University of Birmingham expands cancer research capabilities by giving key opinion leaders advanced tools, technology and expertise.

“Working in partnership with premier research institutions like Johns Hopkins and the University of Birmingham represents an outstanding opportunity for PerkinElmer to strengthen collaborations with scientific leaders in biomarker discovery and at the same time gather important input on our technologies,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. “These collaborations further build on our technical expertise that scientists have come to expect from PerkinElmer, and will hopefully help pave the way to better approaches for the diagnosis and treatment of cancer.”

“Prevention, early detection and specifically targeted therapies through the use of biomarker technology, represent the future in cancer management,” said Philip Johnson, M.D., professor, Division of Cancer Studies, University of Birmingham.

These collaborations will become a major driver in the rapidly emerging field of proteomics, developing new technologies for clinical research.